Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024. In the quarter to June 2026, revenue grew 27.1%, EPS grew 2,281.0% and free cash flow fell 94.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PLX
Protalix BioTherapeutics, Inc. (PLX) P/E ratio
As of 16 October 2026, Protalix BioTherapeutics, Inc. (PLX) trades at a P/E ratio of 10.9×. Over the past ten years it has ranged from 0.0× (March 2026) to 67.3× (February 2025); the current reading is higher than 84% of that period. That is above the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 47.0× | 235.71% |
| FY2023 | 14.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 9.7× | (14.06%) |
| Mar 2026 | 11.3× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 30.8× | 70.80% |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MGNX MacroGenics, Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. compare | n/m |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| ALEC Alector, Inc. compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| PLX Protalix BioTherapeutics, Inc. | 10.9× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)